Revised August 3, 2017 BIOGRAPHICAL SUMMARY George R. Pettit Birth: Long Branch, New Jersey Education: B.S., Chemistry, Washington State University, 1952. M.S., (Syn. and Heterocyclic Chem. with Prof. C. Djerassi), Wayne State University, 1954. Ph.D. (Structure and Steroid Chem. with Prof. C. Djerassi), Wayne State University, 1956. Positions: Teaching Assistant, Washington State University, 1950-52, Lecture Demonstrator, Washington State University, 1952. Research Chemist, E. I. DuPont deNemours and Co., Summer 1953. Graduate Teaching Assistant, Wayne State University, 1952-53. Research Fellow, Wayne State University, 1954-56. Senior Research Chemist, Norwich Eaton Pharmaceuticals, Inc.(now Procter and Gamble Co.), 1956-57. Assistant Professor of Chemistry, University of Maine, 1957-61. Associate Professor of Chemistry, University of Maine, 1961-65. Professor of Chemistry, University of Maine, 1965. Visiting Professor of Chemistry, Stanford University, 1965. Professor of Chemistry, Arizona State University, 1965 - present. Chairman, Organic Division, Arizona State University, 1966-68. Director, Cancer Research Laboratory, 1974-75. Director, Cancer Research Institute, 1975 -. Dalton Professor of Cancer Research and Medicinal Chemistry, 1986 -. Regents Professor of Chemistry, 1990 - present. Co-Director, Arizona Prostate Cancer Task Force, 2000-2010. Honors and Advisory Responsibilities Consultant: Smith-Kline-French Laboratories, 1959-1961. Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, 1965-1976. Special Study Sections, National Cancer Institute and National Institutes of Health, 1976- . Research Vice President and President Oregon State University, 2006 - 2011 Member: Editorial Board, Synthetic Communications, 1970- Journal of Natural Products, l984- 2011, Anti-Cancer Drug Design, 1990- , and Current Organic Chemistry, 1997-2010. Advisory Board, Walter Reed Medical Research Institute, 1985- 1990. The Amer. Inst. of Chemists Chemical Pioneer Award Selection Committee, 1989-97. Corresponding Member, European Organization for Research and Treatment of Cancer (EORTC), 1990- . Research Achievement Awards Committee, American Society of Pharmacognosy, 1996-99. Director, Scientific Advisory Council, International Cancer Advocacy Network (formerly IFADD) 1997- Reviewer, a number of research journals in organic chemistry and cancer, as well as for research grant applications. New York Academy of Sciences, Revised August 3, 2017 Past Member: Cancer Treatment Advisory Board, Division of Cancer Treatment, National Cancer Institute, 1971-1974. Medicinal Chemistry Fellowships Committee, National Institutes of Health, 1967-1970. American Chemical Society Awards Committee, 1968-1971, 1978-81, 1998-2002, 2012-. Washington State University Foundation Board, 1981-1985. Clinical Trials Board, U.K. Cancer Research Campaign 1985-2006 Fellow: American Institute of Chemists, 1970- . American Society of Pharmacognosy, 2007- Represented: Our government in negotiations for exchange of drugs for the treatment of cancer, March 17 - April 14, 1973. Part of the negotiations took place in Moscow, Riga, Leningrad, Kiev, and Yerevan, USSR. U.S. Academy of Sciences in a study of drug development and medicine in the People's Republic of China, June 1974. These responsibilities were performed in Peking, Shanghai, Tienstin, Nanching, Hanchow, and Kwangchow. The National Cancer Institute at a considerable number of university, research institute, and industrial laboratories from 1965. The University of Maine and Arizona State University as a lecturer at a large number of international scientific symposia, national scientific meetings, and at other universities from 1957. Memberships: American Chemical Society The Chemical Society (London) American Society of Clinical Oncology American Pharmacognosy Society American Association for Cancer Research National Academy of Inventors Phi Lambda Upsilon Honors: Washington State University Regents Distinguished Alumnus Award, 2012 Long Branch High Schools, Long Branch, New Jersey, Distinguished Alumni Academic Hall of Fame, 2009 Laverne Weber Visitng Scholar, Hatfield Marine Science Center, Oregon State University, 2009 Distinguished Lecture Series, School of Pharmacy, University of Pittsburgh, 2009 Special Issue of Journal of Natural Products dedicated to Professor G. Robert Pettit, March, 2008 Nolan & Gloria Sommer Award, Univ. of Nebraska, April 2000 Ernest Guenther Award in the Chemistry of Natural Products, American Chemical Society, 1998. Mathias P. Mertes Memorial Lecture Award, University of Kansas, Lawrence, Kansas 1997. Research Achievements Award, American Society of Pharmacognosy, 1995. State of Arizona Governor's Excellence Award, 1993. Regents Professor, Arizona State University, May 1990. Revised August 3, 2017 Outstanding Investigator Award - National Cancer Institute, 1989-2001. Chemical Pioneer Award, American Institute of Chemists, 1988. Appointed Dalton Professor of Medicinal Chemistry and Cancer Research, 1986. Alumni Achievement Award, Washington State University, 1983-1984. Distinguished Research Professorship, Arizona State University, Academic Year 1978-1979. Visiting Professor, South African Universities, Fall 1978. Presented named lecture series at a number of universities. Honorary Memberships: ARCS Foundation PAM Group European Organization for Research and Treatment of Cancer (EORTC). International Cancer Advocacy Network (formerly International Foundation for Anticancer Drug Discovery). Revised August 3, 2017 Publications: Books 1A. G. R. Pettit, SYNTHETIC PEPTIDES, Vol. 1, Van Nostrand Reinhold Co., New York, N.Y., 1970. 2A. G. R. Pettit, SYNTHETIC PEPTIDES, Vol. 2, Van Nostrand Reinhold Co., New York, N.Y., 1971. 3A. G. R. Pettit, SYNTHETIC PEPTIDES, Vol. 3, Academic Press, New York, N.Y., 1975. 4A. G. R. Pettit, SYNTHETIC PEPTIDES, Vol. 4, Elsevier Scientific Publishing Co., Amsterdam, The Netherlands, 1976. 5A. G. R. Pettit, SYNTHETIC PEPTIDES, Vol. 5, Elsevier Scientific Pub. Co., Amsterdam, The Netherlands, 1980. 6A. G. R. Pettit, SYNTHETIC PEPTIDES, Vol. 6, Elsevier Scientific Pub. Co., Amsterdam, The Netherlands, 1982. 7A. G. R. Pettit, SYNTHETIC NUCLEOTIDES, Vol. 1, Van Nostrand Reinhold Co., New York, N.Y., 1972. 8A. G. R. Pettit, BIOSYNTHETIC PRODUCTS FOR CANCER CHEMOTHERAPY, Vol. l, Plenum Publishing Co., New York, N.Y., 1977. 9A. G. R. Pettit and G. M. Cragg, BIOSYNTHETIC PRODUCTS FOR CANCER CHEMOTHERAPY, Vol. 2, Plenum Publishing Co., New York, N.Y., 1978. 10A. G. R. Pettit and R. H. Ode, BIOSYNTHETIC PRODUCTS FOR CANCER CHEMOTHERAPY, Vol. 3, Plenum Publishing Corp., New York, N.Y., 1979. 11A. G. R. Pettit, G. M. Cragg, and C. L. Herald, BIOSYNTHETIC PRODUCTS FOR CANCER CHEMOTHERAPY, Vol. 4, Elsevier Scientific Pub. Co., Amsterdam, 1984. 12A. G. R. Pettit, G. M. Cragg, and C. L. Herald, BIOSYNTHETIC PRODUCTS FOR CANCER CHEMOTHERAPY, Vol. 5, Elsevier Scientific Pub. Co., Amsterdam, 1985. 13A. G. R. Pettit, C. L. Herald, and C. R. Smith, BIOSYNTHETIC PRODUCTS FOR CANCER CHEMOTHERAPY, Vol. 6, Elsevier Scientific Pub. Co., Amsterdam, 1989. 14A. G. R. Pettit, F. Hogan-Pierson, C. L. Herald, ANTICANCER DRUGS FROM ANIMALS, PLANTS, AND MICROORGANISMS, John Wiley-Interscience, New York, 1993. Revised August 3, 2017 Chapters: 1B. G. R. Pettit and E. Van Tamelen, Desulfurization With Raney Nickel in "Organic Reactions," Vol. XII, Ed. by Arthur C. Cope, John Wiley and Sons, Inc., New York, 1962, Chapter 5, pp. 356-529. 2B. R. Ode, Y. Kamano, and G. R. Pettit, Cardenolides and Bufadienolides in "MTP International Review of Science, Organic Chemistry Series One," Vol. 8, Ed. by W. F. Johns, Butterworths, London, 1972, Chapter 6, pp. 151-177. 3B. R. Ode, G. R. Pettit, and Y. Kamano, Cardenolides and Bufadienolides in "International Review of Science, Organic Chemistry Series Two," Vol. 8, Ed. by W. F. Johns, Butterworths, London, 1975, Chapter 6, pp. 145-171. 4B. G. R. Pettit, C. R. Smith, and S. B. Singh, "Recent Advances in the Chemistry of Plant Antineoplastic Constituents," in Biologically Active Natural Products, Annual Proceedings of the Phytochemical Society of Europe, Clarendon Press, Oxford, Chap. 7, 1987, pp. 105-116. 5B. P. M. Blumberg, G. R. Pettit, B. S. Warren, A. Szallasi, L. D. Schuman, N. A. Sharkey, H. Nakakuma, M. L. Dell'Aquila, and D. J. de Vries, "The Protein Kinase C Pathway in Tumor Promotion," In: Skin Carcinogenesis: Mechanisms and Human Relevance, Alan R. Liss, Inc., N.Y., 1989, p. 201-212. 6B. G. R. Pettit, "The Bryostatins," in: Progress in the Chemistry of Organic Natural Products, No. 57, Founded by L. Zechmeister, Ed. by W. Herz, G. W. Kirby, W. Steglich, and Ch. Tamm, Springer-Verlag, New York, 1991, pp. 153-195. 7B. B. Gabrielsen, T. P. Monath, J. W. Huggins, J. J. Kirsi, M. Hollingshead, W. M. Shannon, and G. R. Pettit, “Activity of Selected Amaryllidaceae Constituents and Related Synthetic Substances Against Medically Important RNA Viruses,” in: Natural Products as Antiviral Agents, Ed. by C. K. Chu and H. G. Cutler, Plenum Press, New York, 1992, pp. 121-135. 8B. G. R. Pettit, "The Dolastatins," in Progress in the Chemistry of Organic Natural Products, Vol. 70, Ed. By W. Herz, G. W. Kirby, R. E. Moore, W. Steglich, and Ch. Tamm, Springer Verlag, New York, 1997, pp. 1-79. 9B. G. R. Pettit, C. L. Herald, and F. Hogan, “Biosynthetic Products for Anticancer Drug Design and Treatment: The Bryostatins,” in Anticancer Drug Development, ed. By B. Baguley, Academic Press, San Diego, CA, 2002, pp. 203-235. 10B. G. R. Pettit,